Halozyme Therapeutics Inc.'s Genentech’s Rituxan Hycelatm, which uses Halozyme’s hyaluronidase human enhance technology, was approved by the U.S. Food and Drug Administration for subcutaneous injection in multiple blood cancer indications.
"We are pleased that Rituxan Hycela will now provide another treatment option for U.S. patients," Dr. Helen Torley, Halozyme’s president and CEO, said in a statement. "Rituxan Hycela has the potential to reduce the treatment burden and administration time, and is an option preferred by many patients."
Rituxan Hycela, approved for patients with follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, will be available within a week or two in the United States.
Halozyme Therapeutics is a biotechnology company that develops oncology therapies. Its lead proprietary product, the drug PEGH20, targets solid tumors and is being developed to treat metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies.
Alerts Sign-up